KESTRA MEDICAL TECHNOLOGIES, LTD.
For the period ended Jan 31, 2025. Filed Apr 17, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jan 31, 2025 · Filed Apr 17, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Use of Proceeds from Initial Public Offering of Common Shares
On March 7, 2025 we completed the initial public offering of our Common Shares pursuant to a registration statement on Form S-1 (File No. 333-284807), which was declared effective on March 5, 2025. Under the registration statement, we sold an aggregate of 13,664,704 Common Shares at the public offering price of $17.00 per share. This included 1,782,352 Common Shares issued by the Company pursuant to the option to purchase additional shares granted to the underwriters. BofA Securities, Inc., Goldman Sachs & Co. LLC and Piper Sandler & Co. acted as representatives of the underwriters for the offering. We received net proceeds, after deducting underwriting discounts and commissions and before deducting estimated offering costs, of approximately $215.8 million. There has been no material change in the use of proceeds as described in the IPO Prospectus.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.